![]() Track D will place attention on the impact of the COVID-19 pandemic on models of service delivery and adaptations, service availability and uptake and strategies employed by health systems, service providers and individuals to mitigate the impact of service disruptions. The track will also focus on structural interventions for HIV prevention and treatment, including advances in measuring and supporting adherence and retention, and factors that promote or impede the translation of social, behavioural and structural evidence into practice at all levels (global, national, local, community and individual). These factors include the effectiveness of treatment, care and support strategies for people living with HIV and HIV prevention methods for those most vulnerable to HIV acquisition. ![]() Social and behavioural science will facilitate the discovery-policy-implementation trajectory through qualitative, quantitative and mixed-methods assessments of social and behavioural factors influencing HIV vulnerability, clinical outcomes and intervention impact. A major focus will also be on next-generation HIV prevention trial designs, which can assess new advances in the context of high-efficacy options.ĭownload the full list of Track C abstract submission categories The track will assess best practices for greater inclusion of key groups such as the “missing men”, adolescent girls and young women, marginalized and refugee populations, people who use drugs, men who have sex with men, transgender people and Indigenous peoples. ![]() Track C will present advances in prevention tools along with assessments of where and why HIV incidence densities remain too high to end the epidemic, as well as explore the impacts of COVID-19 on HIV prevention programmes, HIV testing, ART initiation and PrEP programmes. Interventions aimed at reducing HIV transmission and acquisition are fundamental to achieving the goal of ending the HIV epidemic, but progress has been limited by suboptimal coverage, uptake, adherence and persistence. Highlights will include advances in combining immunotherapeutic agents to achieve ARV-free remission of HIV viremia, novel insights into the nature of the HIV reservoir and mechanisms of persistence, advances towards vaccine-mediated elicitation of broadly neutralizing antibodies (bNAbs), innovations in PrEP- and bNAb-mediated interruption of HIV transmission, intersections between the HIV and COVID-19 pandemics, and progress towards understanding the drivers and implications of ongoing immuno-metabolism and inflammation in ARV-treated individuals, including the impact of CMV and COVID-19 on people living with HIV.ĭownload the full list of Track A abstract submission categoriesĮpidemiology and prevention science will explore the HIV prevention toolkit, which is expanding with vaginal rings, long-acting oral and injectable PrEP, new HIV testing modalities, bNAbs and programmatic innovations. A strong resurgence of progress in these areas can be anticipated as COVID-19 restrictions begin to lift, underscoring the AIDS 2022 theme to Re-engage and follow the science.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |